Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

VCYT

(VCYT)

NGM – Real vaqt narxi. Valyuta: USD

30.01

-2.79 (-8.51%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

30.01

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 7:31 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?

Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte Names Kevin Haas as Chief Development and Technology Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #CancerDiagnostics--Veracyte Names Kevin Haas as Chief Development and Technology Officer.

Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises

Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises

VCYT posts a 47% y/y Q4 earnings jump and 18.5% revenue growth, beats estimates, lifts margins and sees shares rise after hours.

Artisan Global Discovery Fund Q4 2025 Winners, Laggards, Buys & Sells

Artisan Global Discovery Fund Q4 2025 Winners, Laggards, Buys & Sells

The portfolio generated strong absolute returns in Q4 and 2025 but trailed the MSCI All Country World Small Mid Index over each period. Stock selection in health care was the strongest contributor to performance for both the quarter and year. Management highlighted strong demand for high-speed optical components supporting AI-driven data center growth, alongside improving margins.

Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript

Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) Q4 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.36 per share a year ago.

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025. “We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter,” said Marc Stapley, Veracyte's chief executive officer. “We are achieving this growth while mai.

Videolar

No Data

There is no data to display

Press-relizlar

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte Names Kevin Haas as Chief Development and Technology Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #CancerDiagnostics--Veracyte Names Kevin Haas as Chief Development and Technology Officer.

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

25.02.2026

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025. “We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter,” said Marc Stapley, Veracyte's chief executive officer. “We are achieving this growth while mai.

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCOGU--Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium.

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Financial Results For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report: Total revenue of between $138 million and $140 million, an increase of between 16% and 18% Testing revenue of.